Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: A double-blind, randomized, cross-over clinical trial

Nutrition Journal

Volumn 14, Issue 1, 2015, Pages 1-6

  Cicero, Arrigo FG ^a,b   Rosticci, Martina ^a   Parini, Angelo ^a   Morbini, Martino ^a   Urso, Riccardo ^a   Grandi, Elisa ^a   Borghi, Claudio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Hypertension Research Center   (Italy)

Author keywords

Berberine; Chlorogenic acid; Insulin sensitivity; Lipoproteins; Liver steatosis; Nutraceutical

Indexed keywords

ALPHA TOCOTRIENOL; ASPARTATE AMINOTRANSFERASE; BERBERINE; CHLOROGENIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FATTY LIVER; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID ACCUMULATION PRODUCT INDEX; METABOLIC PARAMETERS; MIDDLE AGED; OBESITY; RANDOMIZED CONTROLLED TRIAL; BLOOD; COMPLICATION; DIETARY SUPPLEMENT; FEMALE; HYPERLIPIDEMIAS; MALE; TIME; TREATMENT OUTCOME;

ADULT; AGED; BERBERINE; CHLOROGENIC ACID; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY LIVER; FEMALE; HUMANS; HYPERLIPIDEMIAS; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; TIME; TOCOTRIENOLS; TREATMENT OUTCOME;

EID: 84928573383     PISSN: None     EISSN: 14752891     Source Type: Journal    
DOI: 10.1186/s12937-015-0019-y     Document Type: Article

References (28)

1. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766-81.
2. Yang Z, Zhang N. The burden of overweight and obesity on long-term care and Medicaid financing. Med Care. 2014;52(7):658-63.
3. Bauer UE, Briss PA, Goodman RA, Bowman BA. Prevention of chronic disease in the 21st century: elimination of the leading preventable causes of premature death and disability in the USA. Lancet. 2014;384(9937):45-52.
4. Kones R, Rumana U. Prevention of cardiovascular disease: updating the immensity of the challenge and the role of risk factors. Hosp Pract. 2014;42(1):92-100.
5. Ebbert JO, Elrashidi MY, Jensen MD. Managing overweight and obesity in adults to reduce cardiovascular disease risk. Curr Atheroscler Rep. 2014;16(10):445.
6. Rueda-Clausen CF, Padwal RS. Pharmacotherapy for weight loss. BMJ. 2014;348:g3526.
7. Magrone T, Perez de Heredia F, Jirillo E, Morabito G, Marcos A, Serafini M. Functional foods and nutraceuticals as therapeutic tools for the treatment of diet-related diseases. Can J Physiol Pharmacol. 2013;91(6):387-96.
8. Conroy KP, Davidson IM, Warnock M. Pathogenic obesity and nutraceuticals. Proc Nutr Soc. 2011;70(4):426-38.
9. Cicero AF, Tartagni E, Ertek S. Nutraceuticals for metabolic syndrome management: from laboratory to benchside. Curr Vasc Pharmacol. 2014;12(4):565-71.
10. Klose S, Borner K. Enzymatic determination of total cholesterol with the Greiner Selective Analyzer (GSA II). J Clin Chem Clin Biochem. 1977;15:121-30.
11. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345-53.
12. Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: Bermeyer H, editor. Methods of Enzymatic Analysis. 2nd English ed. New York: Academic Press; 1974. p. 18-31.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
15. van Dam RM, Feskens EJM. Coffee consumption and risk of type 2 diabetes mellitus. Lancet. 2002;360(9344):1477-8.
16. Cicero AFG, D'Addato S, Reggi A, Marchesini Reggiani G, Borghi C, on behalf of the Brisighella Heart Study. Hepatic Steatosis Index and Lipid Accumulation Product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study. Intern Emerg Med. 2013;8(3):265-7.
17. McCarty MF. A chlorogenic acid-induced increase in GLP-1 production may mediate the impact of heavy coffee consumption on diabetes risk. Med Hypotheses. 2005;64(4):848-53.
18. Oboh G, Agunloye OM, Adefegha SA, Akinyemi AJ, Ademiluyi AO. Caffeic and chlorogenic acids inhibit key enzymes linked to type 2 diabetes (in vitro): a comparative study. J Basic Clin Physiol Pharmacol. 2015;26(2):165-70.
19. Li SY, Chang CQ, Ma FY, Yu CL. Modulating effects of chlorogenic acid on lipids and glucose metabolism and expression of hepatic peroxisome proliferator-activated receptor-alpha in golden hamsters fed on high fat diet. Biomed Environ Sci. 2009;22(2):122-9.
20. Ong KW, Hsu A, Tan BK. Anti-diabetic and anti-lipidemic effects of chlorogenic acid are mediated by ampk activation. Biochem Pharmacol. 2013;85(9):1341-51.
21. Chen S, Teoh NC, Chitturi S, Farrell GC. Coffee and non-alcoholic fatty liver disease: brewing evidence for hepatoprotection? J Gastroenterol Hepatol. 2014;29(3):435-41.
22. Cicero AFG, Ertek S. Metabolic and cardiovascular effects of berberine: from preclinical evidences to clinical trial results. Clin Lipidol. 2009;4(5):553-63.
23. Derosa G, Maffioli P, Cicero AFG. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther. 2012;12(8):1113-24.
24. Cicero AFG, Derosa G, Maffioli P, Reggi A, Parini A, Rosticci M, et al. Berberine induced improvement in Hepatic Steatosis Index in overweight dyslipidaemic patients treated with lipid-lowering nutraceuticals. Curr Topics Nutr Res. 2013;11(1-2):41-6.
25. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162.
26. Gruben N, Shiri-Sverdlov R, Koonen DP, Hofker MH. Nonalcoholic fatty liver disease: A main driver of insulin resistance or a dangerous liaison? Biochim Biophys Acta. 2014;1842(11):2329-43.
27. Cicero AF, Dormi A, D'Addato S, Gaddi AV, Borghi C. Long-term effect of a dietary education program on postmenopausal cardiovascular risk and metabolic syndrome: the Brisighella Heart Study. J Womens Health. 2010;19(1):133-7.
28. Nseir W, Hellou E, Assy N. Role of diet and lifestyle changes in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(28):9338-44.